Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
CLDX filed a patent for "anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs" on Fri, March 3, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
